Chronic constipation in the elderly: a primer for the gastroenterologist

BMC Gastroenterology

Giuseppe Chiarioni¹  Franco Bazzoli²  Leonardo H. Eusebi²  Vincenzo Stanghellini²  Eugenio Ruggeri²  Roberto De Giorgio² 

[1] Division of Gastroenterology of the University of Verona, Ospedale Policlinico GB Rossi, Piazzale LA Scuro, 10, Verona, 37134, Italy;Department of Medical and Surgical Sciences/Digestive system, University of Bologna and St. Orsola-Malpighi Hospital, Bologna, Italy

关键词: Laxatives;    Constipation;    Irritable bowel syndrome;    Fecal impaction;    Elderly;   

Others  :  1234380
DOI  :  10.1186/s12876-015-0366-3

 received in 2015-04-16, accepted in 2015-10-04,  发布年份 2015

【 摘 要 】

Constipation is a frequently reported bowel symptom in the elderly with considerable impact on quality of life and health expenses. Disease-related morbidity and even mortality have been reported in the affected frail elderly. Although constipation is not a physiologic consequence of normal aging, decreased mobility, medications, underlying diseases, and rectal sensory-motor dysfunction may all contribute to its increased prevalence in older adults. In the elderly there is usually more than one etiologic mechanism, requiring a multifactorial treatment approach. The majority of patients would respond to diet and lifestyle modifications reinforced by bowel training measures. In those not responding to conservative treatment, the approach needs to be tailored addressing all comorbid conditions. In the adult population, the management of constipation continues to evolve as well as the understanding of its complex etiology. However, the constipated elderly have been left behind while gastroenterology consultations for this common conditions are at a rise for the worldwide age increment. Aim of this review is to provide an update on epidemiology, quality of life burden, etiology, diagnosis, current approaches and limitations in the management of constipation in the older ones to ease the gastroenterologists’ clinic workload.

【 授权许可】

   
2015 De Giorgio et al.

【 参考文献 】

• [1]Higgins PD, Johanson JF: Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004, 99:750-9.
• [2]Bharucha AE, Pemberton JH, Locke GR III: American Gastroenterological Association technical review on constipation. Am Gastroenterol Assoc Gastroenterol 2013, 144:218-38.
• [3]Glia A, Lindberg G: Quality of life in patients with different types of functional constipation. Scand J Gastroenterol 1997, 32:1083-9.
• [4]Wald A, Scarpignato C, Kamm MA: The burden of constipation on quality of life: results of a multinational survey. Aliment Pharmacol Ther. 2007, 26:227-36.
• [5]Charach G, Greenstein A, Rabinovich P, Groskopf I, Weintraub M: Alleviating constipation in the elderly improves lower urinary tract symptoms. Gerontology 2001, 47:72-6.
• [6]Berardi RS, Lee S: Stercoraceous perforation of the colon. Report of a case. Dis Colon Rectum 1983, 26:283-6.
• [7]Wrenn K: Fecal impaction. N Engl J Med 1989, 321:658-62.
• [8]Bharucha AE, Dorn SD, Lembo A, Pressman A: American gastroenterological association medical position statement on constipation. Gastroenterology 2013, 144:211-7.
• [9]Neri L, Basilisco G, Corazziari E: Constipation severity is associated with productivity losses and healthcare utilization in patients with chronic constipation. United European Gastroenterol J. 2014, 2:138-47.
• [10]Dennison C, Prasad M, Lloyd A, Bhattacharyya SK, Dhawan R, Coyne K: The health-related quality of life and economic burden of constipation. Pharmacoeconomics. 2005, 23:461-76.
• [11]Menees SB, Guentner A, Chey SW, Saad R, Chey WD. How Do US Gastroenterologists Use Over-the-Counter and Prescription Medications in Patients With Gastroesophageal Reflux and Chronic Constipation?. Am J Gastroenterol 2015, in press.
• [12]Harari D: Constipation. In Hazzard’s Geriatric Medicine and Gerontology. 6th edition. Edited by Halter JB, Ouslander JG, Tinetti ME. McGraw-Hill Companies, New York, USA; 2009:1103-22.
• [13]Harris LA: Prevalence and ramifications of chronic constipation. Manag Care Interface 2005, 18:23-30.
• [14]Whitehead WE, Drinkwater D, Cheskin LJ, Heller BR, Schuster MMJ: Constipation in the elderly living at home. Definition, prevalence, and relationship to lifestyle and health status. Am Geriatr Soc 1989, 37:423-9.
• [15]Morley JE, Kim MJ, Haren MT, Kevorkian R, Banks WA: Frailty and the aging male. Aging male 2005, 8(3–4):135-40.
• [16]Wolfsen CR, Barker JC, Mitteness LS: Constipation in the daily lives of frail elderly people. Arch Fam Med 1993, 2:853-8.
• [17]Fox JC, Fletcher JG, Zinsmeister AR, Seider B, Riederer SJ: Bharucha AE. Effect of aging on anorectal and pelvic floor functions in females. Dis Colon Rectum. 2006, 49:1726-35.
• [18]Werta BL, Williams KA, Pont LG. A longitudinal study of constipation and laxative use in a community-dwelling elderly population. Arch Gerontol Gertiatr. 2015, in press
• [19]Crane SJ, Talley NJ: Chronic gastrointestinal symptoms in the elderly. Clin Geriatr Med 2007, 23:721-34.
• [20]Kimberly BS: Constipation in the elderly: implication in skilled nursing facilities. Director 2007, 15:20-3.
• [21]Coyne KS, Cash B, Kopp Z, Murphy S, Smith GJ, Davidson GA: The prevalence of chronic constipation and fecal incontinence among men and women with symptoms of overactive bladder. BJU Int. 2011, 107:254-61.
• [22]Bouras EP, Tangalos EG: Chronic constipation in the elderly. Gastroenterol Clin North Am 2009, 38:463-80.
• [23]Kinnunen O: Study of constipation in a geriatric hospital, day hospital, old people’s home and at home. Aging 1991, 3:161-70.
• [24]Lim SF, Ong SY, Tan YL, Ng YS, Chan YH, Childs C. Incidence and predictors of new-onset constipation during acute hospitalisation after stroke. Int J Clin Pract 2015, in press doi:10.1111/ijcp.12528
• [25]Rao SS, Seaton K, Miller MJ, et al.: Psychological profiles and quality of life differ between patients with dyssynergia and those with slow transit constipation. J Psychosom Res 2007, 63:441-9.
• [26]O’Keefe EA, Talley NJ, Tangalos EG, Zinsmeister AR: A bowel symptom questionnaire for the elderly. J Gerontol. 1992, 47:M116-21.
• [27]Talley NJ: Definitions, epidemiology, and impact of chronic constipation. Rev Gastroenterol Disord 2004, 4(Suppl 2):S3-10.
• [28]Pare P, Ferrazzi S, Thompson WG, Irvine EJ, Rance L: An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol. 2001, 96:3130-7.
• [29]Bassotti G, Chiarioni G, Vantini I, et al.: Anorectal manometric abnormalities and colonic propulsive impairment in patients with severe chronic idiopathic constipation. Dig Dis Sci 1994, 39:1558-64.
• [30]Cook IJ, Talley NJ, Benninga MA, Rao SS, Scott SM: Chronic constipation: overview and challenges. Neurogastroenterol Motil. 2009, 21(Suppl 2):1-8.
• [31]Rao SS: Constipation: evaluation and treatment of colonic and anorectal motility disorders. Gastroenterol Clin North Am 2007, 36:687-711.
• [32]Koch TR, Carney JA, Go VL, Szurszewski JH: Inhibitory neuropeptides and intrinsic inhibitory innervation of descending human colon. Dig Dis Sci. 1991, 36:712-8.
• [33]Bassotti G, Villanacci V: Can “functional” constipation be considered as a form of enteric neuro-gliopathy? Glia 2011, 59:345-50.
• [34]Camilleri M, Lee JS, Viramontes B, Bharucha AE, Tangalos EG: Insights into the pathophysiology and mechanisms of constipation, irritable bowel syndrome, and diverticulosis in older people. J Am Geriatr Soc. 2000, 48:1142-50.
• [35]Varma JS, Bradnock J, Smith RG, Smith AN: Constipation in the elderly. A physiologic study. Dis Colon Rectum 1988, 31:111-5.
• [36]Knowles CH, Farrugia G: Gastrointestinal neuromuscular pathology in chronic constipation. Best Pract Res Clin Gastroenterol 2011, 25:43-57.
• [37]Szurszewski JH, Holt PR, Schuster M: Proceedings of a workshop entitled “Neuromuscular function and dysfunction of the gastrointestinal tract in aging”. Dig Dis Sci 1989, 34:1135-46.
• [38]Klosterhalfen B, Offner F, Topf N, Vogel P, Mittermayer C: Sclerosis of the internal anal sphincter, a process of aging. Dis Colon Rectum. 1990, 33:606-9.
• [39]Papachrysostomou M, Pye SD, Wild SR, Smith AN: Significance of the thickness of the anal sphincters with age and its relevance in fecal incontinence. Scand J Gastroenterol. 1994, 29:710-4.
• [40]Lovell R, Ford A: Global prevalence of, and risk factors for, irritable bowel syndrome: a meta- analysis. Clin Gastroenterol Hepatol 2012, 10:712-21.
• [41]Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC: Functional bowel disorders. Gastroenterology. 2006, 130:1480-9.
• [42]Bassotti G, Maggio D, Battaglia E, et al.: Manometric investigation of anorectal function in early and late stage Parkinson’s disease. J Neurol Neurosurg Psychiatry 2000, 68:768-70.
• [43]Iovino P, Chiarioni G, Bilancio G, et al.: New onset of constipation during long-term physical inactivity: a proof-of-concept study on the immobility-induced bowel changes. PLoS One 2013, 20:e72608.
• [44]Spiller R, Camilleri M, Longstreth GF: Do the symptom-based, Rome criteria of irritable bowel syndrome lead to better diagnosis and treatment outcomes? Clin Gastroenterol Hepatol 2010, 8:125-9.
• [45]Saad RJ, Rao SS, Koch KL, et al.: Do stool form and frequency correlate with whole-gut and colonic transit? Results from a multicenter study in constipated individuals and healthy controls. Am J Gastroenterol 2010, 105:403-11.
• [46]Chiarioni G, Kim SM, Vantini I, Whitehead WE: Validation of the balloon evacuation test: reproducibility and agreement with findings from anorectal manometry and electromyography. Clin Gastroenterol Hepatol 2014, 12:2049-54.
• [47]Tack J, Müller-Lissner S, Stanghellini V: Diagnosis and treatment of chronic constipation--a European perspective. Neurogastroenterol Motil. 2011, 23:697-710.
• [48]Bassotti G, Stanghellini V, Chiarioni G, et al.: Upper gastrointestinal motor activity in patients with slow-transit constipation. Further evidence for an enteric neuropathy. Dig Dis Sci 1996, 41:1999-2005.
• [49]Redmond JM, Smith GW, Barofsky I, Ratych RE, Goldsborough DC, Schuster MM: Physiological tests to predict long-term outcome of total abdominal colectomy for intractable constipation. Am J Gastroenterol. 1995, 90:748-53.
• [50]Arora Z, Parungao JM, Lopez R, Heinlein C, Santisi J, Birgisson S: Clinical Utility of Wireless Motility Capsule in Patients with Suspected Multiregional Gastrointestinal Dysmotility. Dig Dis Sci 2015, 60:1350-7.
• [51]Chiarioni G, Heymen S, Whitehead WE: Biofeedback therapy for dyssynergic defecation. World J Gastroenterol 2006, 12:7069-74.
• [52]Andersson H, Bosaeus I, Falkheden T, Melkersson M: Transit time in constipated geriatric patients during treatment with a bulk laxative and bran: a comparison. Scand J Gastroenterol. 1979, 14:821-6.
• [53]Nour-Eldein H, Salama HM, Abdulmajeed AA, Heissam KS: The effect of lifestyle modification on severity of constipation and quality of life of elders in nursing homes at Ismailia city, Egypt. J Family Community Med 2014, 21:100-6.
• [54]Ford AC, Moayyedi P, Lacy BE, et al.: American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation. Am J Gastroenterol 2014, 109:S2-26.
• [55]Spinzi G, Amato A, Imperiali G, et al.: Constipation in the elderly: management strategies. Drugs Aging 2009, 26:469-74.
• [56]Suares NC, Ford AC: Systematic review: the effects of fibre in the management of chronic idiopathic constipation. Aliment Pharmacol Ther 2011, 33:895-901.
• [57]Fleming V, Wade WE: A review of laxative therapies for treatment of chronic constipation in older adults. Am J Geriatr Pharmacother 2010, 8:514-50.
• [58]Attaluri A, Donahoe R, Valestin J, Brown K, Rao SSC: Randomised clinical trial: dried plums (prunes) vs. psyllium for constipation. Aliment Pharmacol Ther 2011, 33:822-8.
• [59]Miller LE, Ouwehand AC: Probiotic supplementation decreases intestinal transit time: meta-analysis of randomized controlled trials. World J Gastroenterol 2013, 19:4718-25.
• [60]Chiarioni G, Whitehead WE: Biofeedback therapy for constipation. In GI Motility Testing: a Laboratory and Office Handbook. Edited by Parkman HP, McCallum RW, Rao SSC. Slack Inc, Thorofare, NJ; 2011:179-87.
• [61]Simón MA, Bueno AM: Behavioural treatment of the dyssynergic defecation in chronically constipated elderly patients: a randomized controlled trial. Appl Psychophysiol Biofeedback 2009, 34:273-7.
• [62]Rao SSC, Go JT: Update on the management of constipation in the elderly: new treatment options. Clin Interv Aging 2010, 5:163-71.
• [63]Passmore AP, Davies KW, Flanagan PG, Stoker C, Scott MG: A comparison of Agiolax and lactulose in elderly patients with chronic constipation. Pharmacology 1993, 47(Suppl 1):249-52.
• [64]Connolly P, Hughes IW, Ryan G: Comparison of “Duphalac” and “irritant” laxatives during and after treatment of chronic constipation: a preliminary study. Curr Med Res Opin 1975, 2:620-5.
• [65]Lederle FA, Busch DL, Mattox KM, West MJ, Ask DM: Cost-effective treatment of constipation in the elderly. A randomized double-blind comparison of sorbitol and lactulose. Am J Med 1990, 89:597-601.
• [66]Miller LE, Tennilä J, Ouwehand AC: Efficacy and tolerance of lactitol supplementation for adult constipation: a systematic review and meta-analysis. Clin Exp Gastroenterol 2014, 7:241-8.
• [67]Ouwehand AC, Tiihonen K, Saarinen M, Putaala H, Rautonen N: Influence of a combination of Lactobacillus acidophilus NCFM and lactitol on healthy elderly: intestinal and immune parameters. Br J Nutr 2009, 101:367-75.
• [68]De Giorgio R, Cestari R, Corinaldesi R, et al.: Use of macrogol 4000 in chronic constipation. Eur Rev Med Pharmacol Sci 2011, 15:960-6.
• [69]DiPalma JA, Cleveland MV, McGowan J, Herrera HL: A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol 2007, 102:1436-41.
• [70]Corazziari E, Badiali D, Bazzocchi G, et al.: Long term efficacy, safety, and tolerabilitity of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. Gut 2000, 46:522-6.
• [71]DiPalma JA, Cleveland MB, McGowan J, Herrera HL: A comparison of polyethylene glycol laxative and placebo for relief of constipation from constipating medications. South Med J 2007, 100(11):1085-90.
• [72]Chapman RW, Stanghellini V, Geraint M, Halphen M: Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol 2013, 108:1508-15.
• [73]Belsey JD, Geraint M, Dixon TA: Systematic review and meta analysis: polyethylene glycol in adults with non-organic constipation. Int J Clin Pract 2010, 64:944-55.
• [74]Crowell MD, Harris LA, Lunsford TN, Dibaise JK: Emerging drugs for chronic constipation. Expert Opin Emerg Drugs. 2009, 14:493-504.
• [75]Crowell MD, Harris LA, Dibaise JK, Olden KW: Activation of type-2 chloride channels: a novel therapeutic target for the treatment of chronic constipation. Curr Opin Investig Drugs. 2007, 8:66-70.
• [76]Lacy BE, Levy LC: Lubiprostone: a novel treatment for chronic constipation. Clin Interv Aging 2008, 3:357-64.
• [77]Barish CF, Drossman D, Johanson JF, Ueno R: Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci. 2010, 55:1090-7.
• [78]Johanson JF, Morton D, Geenen J, Ueno R: Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol. 2008, 103:170-7.
• [79]Johanson JF, Ueno R: Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 2007, 25:1351-61.
• [80]Gras-Miralles B, Cremonini F: A critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly. Clin Interv Aging 2013, 8:191-200.
• [81]Layer P, Stanghellini V: Review article: Linaclotide for the management of irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2014, 39(4):371-84.
• [82]Lacy BE, Levenick JM, Crowell M: Chronic constipation: new diagnostic and treatment approaches. Ther Adv Gastroenterol 2012, 5:233-47.
• [83]Lembo AJ, Kurtz CB, Macdougall JE, et al.: Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 2010, 138:886-95.
• [84]Rao SS, Quigley EM, Shiff SJ, et al.: Effect of Linaclotide on Severe Abdominal Symptoms in Patients with Irritable Bowel Syndrome with Constipation. Clin Gastroenterol Hepatol 2014, 12:616-23.
• [85]De Giorgio R, Barbara G, Furness JB, Tonini M: Novel therapeutic targets for enteric nervous system disorders. Trends Pharmacol Sci. 2007, 28:473-81.
• [86]Quigley EMM: Prucalopride: safety, efficacy and potential applications. Ther Adv Gastroenterol 2012, 5:23-30.
• [87]Tack J, Stanghellini V, Dubois D, Joseph A, Vandeplassche L, Kerstens R: Effect of prucalopride on symptoms of chronic constipation. Neurogastroenterol Motil 2014, 26:21-7.
• [88]Muller-Lissner S, Rykx A, Kerstens R, Vandeplassche L: A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil 2010, 22:991-8.
• [89]Camilleri M, Beyens G, Kerstens R, Robinson P, Vandeplassche L: Safety assessment of prucalopride in elderly patients with constipation: A double blind, placebo-controlled study. Neurogastroenterol Motil. 2009, 21:1256-63.
• [90]Goldberg M, Li YP, Johanson JF, et al.: Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation -a 4-week, randomized, double-blind, placebo-controlled, dose–response study. Aliment Pharmacol Ther 2010, 32:1102-12.
• [91]Camilleri M, Vazquez-Roque MI, Burton D, et al.: Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil 2007, 19:30-8.
• [92]Chey WD, Camilleri M, Chang L, Rikner L, Graffner H: A randomized placebo-controlled phase IIb trial of A3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol. 2011, 106:1803-12.
• [93]Shailubhai K, Comiskey S, Foss JA, et al.: Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastro- intestinal tract, is safe and well-tolerated in single doses. Dig Dis Sci 2013, 58:2580-6.
• [94]Miner PB, Surowitz R, Fogel R, et al.: Plecanatide, a novel guanylate-cyclase C (GC-C) receptor agonist, is efficacious and safe in patients with chronic idiopathic constipation (CIC): results from a 951 patient, 12 week, multi-center trial. Digestive Diseases Week. Orange County Convention Center, Orlando, FL; 2013.